[HTML][HTML] Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade?
A Oueslati - Journal of Parkinson's disease, 2016 - content.iospress.com
Abnormal accumulation of proteinaceous intraneuronal inclusions called Lewy bodies (LBs)
is the neurpathological hallmark of Parkinson's disease (PD) and related synucleinopathies …
is the neurpathological hallmark of Parkinson's disease (PD) and related synucleinopathies …
Molecular and therapeutic potential and toxicity of valproic acid
Valproic acid (VPA), a branched short‐chain fatty acid, is widely used as an antiepileptic
drug and a mood stabilizer. Antiepileptic properties have been attributed to inhibition of …
drug and a mood stabilizer. Antiepileptic properties have been attributed to inhibition of …
Multiple roles of HDAC inhibition in neurodegenerative conditions
DM Chuang, Y Leng, Z Marinova, HJ Kim… - Trends in neurosciences, 2009 - cell.com
Histone deacetylases (HDACs) play a key role in homeostasis of protein acetylation in
histones and other proteins and in regulating fundamental cellular activities such as …
histones and other proteins and in regulating fundamental cellular activities such as …
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
SM Hammond, G Hazell… - Proceedings of the …, 2016 - National Acad Sciences
The development of antisense oligonucleotide therapy is an important advance in the
identification of corrective therapy for neuromuscular diseases, such as spinal muscular …
identification of corrective therapy for neuromuscular diseases, such as spinal muscular …
Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
IF Harrison, DT Dexter - Pharmacology & therapeutics, 2013 - Elsevier
Parkinson's disease (PD) is the most common movement disorder affecting more than 4
million people worldwide. The primary motor symptoms of the disease are due to …
million people worldwide. The primary motor symptoms of the disease are due to …
Alpha-synuclein, lipids and Parkinson's disease
V Ruipérez, F Darios, B Davletov - Progress in lipid research, 2010 - Elsevier
Parkinson's disease is the second most common neurodegenerative disease, after
Alzheimer's disease, among the aging human population. The main symptoms of …
Alzheimer's disease, among the aging human population. The main symptoms of …
Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection
B Monti, E Polazzi… - Current molecular …, 2009 - ingentaconnect.com
Valproic acid (VPA, 2-propylpentanoic acid) has been widely used as an antiepileptic drug
and for the therapy of bipolar disorders for several years. Its mechanism of action was …
and for the therapy of bipolar disorders for several years. Its mechanism of action was …
α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity
We recently demonstrated that protein kinase Cδ (PKCδ), an important member of the novel
PKC family, is a key oxidative stress-sensitive kinase that can be activated by caspase-3 …
PKC family, is a key oxidative stress-sensitive kinase that can be activated by caspase-3 …
Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of α-synuclein
Valproic acid (VPA), an established antiepileptic and antimanic drug, has recently emerged
as a promising neuroprotective agent. Among its many cellular targets, VPA has been …
as a promising neuroprotective agent. Among its many cellular targets, VPA has been …
[HTML][HTML] The cerebellar dopaminergic system
P Flace, P Livrea, GA Basile, D Galletta… - Frontiers in systems …, 2021 - frontiersin.org
In the central nervous system (CNS), dopamine (DA) is involved in motor and cognitive
functions. Although the cerebellum is not been considered an elective dopaminergic region …
functions. Although the cerebellum is not been considered an elective dopaminergic region …